双色球篮球杀号澳客网: Lonza Reports Positive Start to 2018 with Businesses Along the Healthcare Continuum as Growth Drivers

May 04,2018

澳客网安全吗 www.16mfy.com.cn ?? Continued strong demand for pharma offerings in Clinical Development and Manufacturing and Commercial Manufacturing and for Consumer Health offerings

?? The former Capsugel business, now part of Lonza Pharma & Biotech and Lonza Consumer Health, performed well in Q1, and integration continues as planned

?? Start of production in the world’s largest dedicated cell-and-gene-therapy manufacturing facility in Pearland, Greater Houston, TX (USA) adds to global technology footprint and innovative offerings

?? Announcing mid-scale biologics manufacturing expansion and state-of-the-art technological advances at Lonza's Portsmouth, NH (USA) site

?? First milestone achieved for a positive half-year result 2018

Basel, Switzerland, 4 May 2018 -- Lonza had a positive start to 2018 led by the businesses along the healthcare continuum. The former Capsugel business, now part of Lonza Pharma & Biotech and Lonza Consumer Health, has shown a strong performance following good progress on business and functional integration.

In Pharma & Biotech both the biologics and the small-molecule businesses are growth drivers with ongoing demand for clinical and commercial offerings. The growth drivers in Specialty Ingredients have been the Consumer Health and Nutrition business, including legacy Capsugel offerings, and the composite materials business in Consumer Resources & Protection.

The seasonal and cyclical businesses in the agro, wood and water product portfolios had a softer start.

“Our businesses along the healthcare continuum produced positive results. Former Capsugel businesses, in particular, performed above our expectations both versus prior year and on a run-rate basis and contributed to our core activities,” said Richard Ridinger, Lonza’s CEO. “We have further strengthened our technology footprint by adding to our portfolio the world’s largest dedicated cell-and-gene-therapy manufacturing facility in Pearland, Texas, and by expanding our mid-scale mammalian capacity in Portsmouth, NH. We will continue to invest into our innovative offerings, global presence, commercial and operational excellence while reviewing our portfolio as part of our long-term strategic growth path.”

Pharma & Biotech Segment

Lonza's biological businesses are performing strongly with ongoing high demand in Clinical Development and Manufacturing and with Mammalian and Microbial Commercial Manufacturing continuing to benefit from strong interest in all assets.

The small-molecule businesses continue to outperform on top- and bottom-line with considerable contributions from legacy Capsugel's newly added dosage form and delivery system (DFDS) technologies and with multiple projects in discussion that connect the active pharmaceutical ingredients (API) and DFDS offerings.

Pharma hard capsules from the former Capsugel business had a good start in 2018 with a new leadership team and integration activities with Lonza progressing well.

Products and customer services in the bioscience business experienced positive demand, but comprehensive remediation work initiated in 2017 still had an impact on the business.

Research and development (R&D) and innovation projects are ongoing with a sharp focus on accelerating cell-line construction and offerings in drug product services, digitalizing biological upstream and downstream manufacturing and continuing other process improvements. Furthermore, Lonza continues to invest in state-of-the-art technological advances so that Lonza has the footprint that meets customers' diverse needs.

During the recent grand-opening ceremony in Pearland, TX (USA), Lonza executives and industry leaders unveiled the first-of-its-kind cell-and-gene-therapy manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

Lonza announced today that it is investing in new mid-scale assets in its Portsmouth, NH (USA) site for commercial biomanufacturing to meet strong demand and to complement existing small- and large-scale assets within the Lonza network.

Specialty Ingredients Segment

As of 1 January 2018, the Specialty Ingredients segment began operating in three distinct units: a Consumer Health division, a Consumer & Resources Protection division and a Water Care business unit.

The new Consumer Health division addresses the fast-moving consumer goods markets in nutrition, hygiene and personal care. The new Consumer & Resources Protection division addresses the coatings, composites and agricultural markets.

Lonza Consumer Health is showing good momentum across capsules and ingredients. In particular, two leading actives – UCII? ingredient for joint health and Carnipure? ingredient in sports nutrition – are benefiting from high demand. Growth in capsules and dosage forms is especially driven by clean-label specialty polymer solutions.

In Q1 combined offerings continued to attract interest, fueled by more than 30 new dietary supplement product concept launches that join Lonza’s specialty ingredients and former Capsugel's innovative dosage forms. Additional growth momentum is expected due to synergistic geographic expansion across all businesses.

Disinfecting solutions in home and institutional hygiene applications saw continuous growth, driven by increased demand in North America and Europe that resulted from innovations to address regulatory compliance.

Consumer Resources & Protection benefited from robust demand for composite materials in the aerospace and electronics industries and for antimicrobial solutions in other industrial markets. Solid wood preservatives had a soft start in North America and Europe because of unfavorable weather conditions; however, developments in value-adding applications like mold control and fire protection and in engineered wood are promising.

The agricultural business experienced low demand in Q1 for cyclical-based products, as already announced with FYR 2017, as well as for chemical custom manufacturing. White biotechnology custom manufacturing saw solid growth and pipeline development, and agro specialties had robust momentum.

The basic-material portfolio restructuring in Consumer & Resources Protection is ongoing with business discontinuation of non-core parts, such as the fertilizer business and other basic materials, while the emphasis on innovative offerings is increasing.

With the seasonal pattern, Water Care's pool season is starting just now. Full focus is on brand restaging and innovation in the Residential business, which has already led to significant business gains within Mass Retail that are expected to materialize in late 2018 and 2019. Water Care's dynamic new business development in the e-commerce space is expected to pick up further in 2018.

The restructuring, business model re-design and strategic review of Lonza's Water Care business are ongoing as previously communicated. As part of an active portfolio management, Lonza has retained an investment bank to advise on all strategic options.

Outlook 2018

Lonza confirms ongoing strong momentum for its businesses along the healthcare continuum and is confident to achieve a positive half-year result 2018.

The strong business momentum also makes Lonza fully confident of achieving, at a minimum, the previously communicated full-year guidance of mid-single-digit sales growth on a comparable basis in line with Mid-Term Guidance 2022 and 100 bps improvement in CORE EBITDA margin in line with Mid-Term Guidance 2022.

With the publication of the half-year results 2018, CORE RONOA (return on net operating assets) will be replaced by ROIC (return on invested capital) as a key performance indicator, and the new mid-term ROIC target will be announced. Lonza will provide historical pro-forma financial data for its ROIC metric and for its new reporting structure in Specialty Ingredients.

Ordinary Annual General Meeting (AGM)

The shareholders of Lonza Group AG are gathering today to decide on numerous agenda items, including the re-elections of Board of Directors members, the election of Albert M. Baehny as the Chairman of the Board of Directors, the election of two new Board members (Angelica Kohlmann and Olivier Verscheure), the approval of the proposed dividend distribution and various compensation votes. The results will be published after completion of the AGM.

Browse All News
Bg
  • 这涉及到正确的历史观问题。中华民族的精气神何时拥有的?一派认为是从来没有,所以要全面学习,一派认为从1921年开始拥有的,以前没有,或者说是反作用的。两派之外, 2019-02-19
  • 湖南省益阳市牵手第十二师二二一团举办“湘疆情深 爱洒兵团”捐赠仪式 2019-02-18
  • 林郑月娥:香港将吸引更多国际知名企业上市 2019-02-17
  • 世界杯开幕 率先入场的竟是群贵州少年 2019-02-16
  • 台媒曝吴建豪离婚 百亿身家娇妻收两封离婚协议书 2019-02-15
  • 隐私条款中国国家地理网 2019-02-14
  • 尽管管理层一任一任地换,但是以每年IPO数量的多少作为反映政绩的主要标志,而对于股市下跌、市值(包括国有股)损失、经济晴雨表失真、投资者利益巨亏等等,则不在考核 2019-02-13
  • 你真没一点脑子,文字是哪个人的,你到说说啊 2019-02-12
  • 中国经济充当了世界经济发展的火车头。但是,作为世界经济火车头的中国,在世界主要经济体股市都走牛的情况下,为何熊途漫漫?这种不正常的现象,背后是我们资本市场的投融 2019-02-12
  • 想捞的人多了,为何仅仅房地产部门这么红火?因为人们想捞,发起传销就合理了? 2019-02-11
  • 北科建泰禾·丽春湖院子 2019-02-10
  • 汶川地震十年后,再访“云上甘堡” 2019-02-09
  • 【网络中国节】端午遇上足球杯 平陆交警夜查全力保平安 2019-02-08
  • 贸易战不会让中美两国经济崩溃,只会让中美国经济更健康地发展。贸易战让市场全开放理论失败。这才是根本。 2019-02-07
  • 中国金花李娜将出战温网元老赛 2019-02-07
  • 490| 702| 627| 761| 593| 392| 545| 610| 147| 139|